drugset / Trial / NCT05444998
Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
explore the efficacy and safety of the combination of nintedanib and paclitaxel in the neoadjuvant treatment of HER2 positive early or locally advanced breast cancer
Timeline
- Start
- 2022-11-01
- Primary completion
- 2023-08-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Intuzumab | Unknown | 6 mg/kg | — |
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | — |
| Subject | pyrrolidone | Unknown | 400 mg | — |